TY - JOUR
TI - The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort
AU - Radin, M.
AU - Sciascia, S.
AU - Erkan, D.
AU - Pengo, V.
AU - Tektonidou, M.G.
AU - Ugarte, A.
AU - Meroni, P.
AU - Ji, L.
AU - Belmont, H.M.
AU - Cohen, H.
AU - Ramires de Jesús, G.
AU - Branch, D.W.
AU - Fortin, P.R.
AU - Andreoli, L.
AU - Petri, M.
AU - Rodriguez, E.
AU - Rodriguez-Pinto, I.
AU - Knight, J.S.
AU - Atsumi, T.
AU - Willis, R.
AU - Gonzalez, E.
AU - Lopez-Pedrera, R.
AU - Rossi Gandara, A.P.
AU - Borges Gualhardo Vendramini, M.
AU - Banzato, A.
AU - Sevim, E.
AU - Barbhaiya, M.
AU - Efthymiou, M.
AU - Mackie, I.
AU - Bertolaccini, M.L.
AU - Andrade, D.
JO - Seminars in Arthritis and Rheumatism
PY - 2019
VL - 49
TODO - 3
SP - 464-468
PB - W.B. Saunders
SN - 0049-0172
TODO - 10.1016/j.semarthrit.2019.04.009
TODO - beta2 glycoprotein 1 antibody;  phospholipid antibody;  biological marker;  phospholipid antibody, adjusted global antiphospholipid syndrome score;  adult;  antiphospholipid syndrome;  Article;  cardiovascular risk;  clinical assessment;  comparative study;  controlled study;  cross-sectional study;  female;  human;  hyperlipidemia;  hypertension;  major clinical study;  male;  medical history;  middle aged;  priority journal;  recurrence risk;  recurrent disease;  thrombosis;  antiphospholipid syndrome;  blood;  clinical trial;  complication;  follow up;  global health;  immunology;  multicenter study;  procedures;  prognosis;  register;  retrospective study;  risk assessment;  risk factor;  severity of illness index;  thrombosis, Antibodies, Antiphospholipid;  Antiphospholipid Syndrome;  Biomarkers;  Cross-Sectional Studies;  Female;  Follow-Up Studies;  Global Health;  Humans;  Male;  Middle Aged;  Prognosis;  Recurrence;  Registries;  Retrospective Studies;  Risk Assessment;  Risk Factors;  Severity of Illness Index;  Thrombosis
TODO - Objectives: To assess whether patients with antiphospholipid syndrome (APS) and history of recurrent thrombosis have higher levels of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) when compared to patients without recurrent thrombosis. Methods: In this cross-sectional study of antiphospholipid antibody (aPL)-positive patients, we identified APS patients with a history of documented thrombosis from the AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”). Data on aPL-related medical history and cardiovascular risk factors were retrospectively collected. The aGAPSS was calculated at Registry entry by adding the points corresponding to the risk factors: three for hyperlipidemia, one for arterial hypertension, five for positive anticardiolipin antibodies, four for positive anti-β2 glycoprotein-I antibodies and four for positive lupus anticoagulant test. Results: The analysis included 379 APS patients who presented with arterial and/or venous thrombosis. Overall, significantly higher aGAPSS were seen in patients with recurrent thrombosis (arterial or venous) compared to those without recurrence (7.8 ± 3.3 vs. 6 ± 3.9, p<0.05). When analyzed based on the site of the recurrence, patients with recurrent arterial, but not venous, thrombosis had higher aGAPSS (8.1 ± SD 2.9 vs. 6 ± 3.9; p<0.05). Conclusions: Based on analysis of our international large-scale Registry of aPL-positive patients, the aGAPSS might help risk stratifying patients based on the likelihood of developing recurrent thrombosis in APS. © 2019 Elsevier Inc.
ER -